acamprosate vs safinamide
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and safinamide. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Xadago
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Safinamide (Xadago) is a drug used with levodopa/carbidopa to treat Parkinson's disease. It helps reduce "off" episodes, where symptoms like stiffness and slowness return.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
Safinamide is used to treat Parkinson's disease. It is for people who take levodopa/carbidopa but still have "off" times. During these times, Parkinson's symptoms like stiffness and slow movement come back.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Safinamide is a MAO-B inhibitor. It works by blocking an enzyme in the brain that breaks down dopamine. This helps increase the amount of dopamine available, which can improve motor control.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Uncontrolled movements (dyskinesia)
- • Falls
- • Feeling sick to your stomach (nausea)
- • Trouble sleeping (insomnia)
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Fall 154
- Hallucination 142
- Dyskinesia 137
- Gait Disturbance 93
- Death 90
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
Safinamide can cause or worsen high blood pressure. It can also cause serotonin syndrome, a dangerous condition, if taken with certain other medicines. Some people taking safinamide have fallen asleep suddenly during normal activities. Safinamide may also cause or worsen uncontrolled movements, hallucinations, and compulsive behaviors. Stopping safinamide suddenly can cause serious withdrawal symptoms.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
Safinamide may harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if safinamide passes into breast milk, so talk to your doctor if you are breastfeeding.
Also Compare, Nearby Drugs
Compare safinamide with
How to Read This acamprosate vs safinamide Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while safinamide sits within the MAO-B Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while safinamide has 616. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or safinamide.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.